Download MendeleyNovel antibody-antibiotic conjugate eliminates intracellular S. aureus.
Lehar, S.M., Pillow, T., Xu, M., Staben, L., Kajihara, K.K., Vandlen, R., DePalatis, L., Raab, H., Hazenbos, W.L., Morisaki, J.H., Kim, J., Park, S., Darwish, M., Lee, B.C., Hernandez, H., Loyet, K.M., Lupardus, P., Fong, R., Yan, D., Chalouni, C., Luis, E., Khalfin, Y., Plise, E., Cheong, J., Lyssikatos, J.P., Strandh, M., Koefoed, K., Andersen, P.S., Flygare, J.A., Wah Tan, M., Brown, E.J., Mariathasan, S.(2015) Nature 527: 323-328
- PubMed: 26536114 Search on PubMed
- DOI: https://doi.org/10.1038/nature16057
- Primary Citation Related Structures:
5D6C - PubMed Abstract:
Staphylococcus aureus is considered to be an extracellular pathogen. However, survival of S. aureus within host cells may provide a reservoir relatively protected from antibiotics, thus enabling long-term colonization of the host and explaining clinical failures and relapses after antibiotic therapy. Here we confirm that intracellular reservoirs of S. aureus in mice comprise a virulent subset of bacteria that can establish infection even in the presence of vancomycin, and we introduce a novel therapeutic that effectively kills intracellular S. aureus. This antibody-antibiotic conjugate consists of an anti-S. aureus antibody conjugated to a highly efficacious antibiotic that is activated only after it is released in the proteolytic environment of the phagolysosome. The antibody-antibiotic conjugate is superior to vancomycin for treatment of bacteraemia and provides direct evidence that intracellular S. aureus represents an important component of invasive infections.
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA.
Organizational Affiliation:
